Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chiltern, a contract research organization, has fully integrated its two early phase units into a single operation branded as Chiltern Early Phase, following the acquisition of Drug Development Solutions in February 2008.
Subscribe to our email newsletter
Chiltern Early Phase provides early phase services for the pharmaceutical industry via its two well-established units in Slough (outside of London) and Dundee, Scotland, according to the company.
With a total of 72 high care beds, 42 of which are based at Ninewells Hospital in Dundee, Chiltern Early Phase can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in first time in man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies, said Chiltern.
Glenn Kerkhof, Chiltern’s CEO, said: “When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert early phase service at reasonable cost.”